Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result

Emma R. Leof, Xuan Zhu, Kari G. Rabe, Jennifer B. McCormick, Gloria M. Petersen, Carmen Radecki Breitkopf

Research output: Contribution to journalArticle

Abstract

Purpose: This study examined whether participants who learned research results related to a germline CDKN2A variant known to be associated with increased risk of pancreatic cancer and malignant melanoma would pursue confirmatory testing and cancer screening, share the genetic information with health care providers and family, and change risk perceptions. Methods: Participants were pancreas research registry enrollees whose biological sample was tested in a research laboratory for the variant. In total, 133 individuals were invited to learn a genetic research result and participate in a study about the disclosure process. Perceived cancer risk, screening intentions, and behaviors were assessed predisclosure, immediately postdisclosure, and six months postdisclosure. Results: Eighty individuals agreed to participate and 63 completed the study. Immediately postdisclosure, carriers reported greater intentions to undergo pancreatic cancer and melanoma screening (p values ≤0.024). Seventy-three percent of carriers (47.5% noncarriers) intended to seek confirmatory testing within six months and 20% (2.5% noncarriers) followed through. All participants shared results with ≥1 family member. More carriers shared results with their health care provider than noncarriers (p = 0.028). Conclusion: Recipients of cancer genetic research results may not follow through with recommended behaviors (confirmatory testing, screening), despite stated intentions. The research result disclosure motivated follow-up behaviors among carriers more than noncarriers.

Original languageEnglish (US)
JournalGenetics in Medicine
DOIs
StatePublished - Jan 1 2019

Fingerprint

Disclosure
Pancreatic Neoplasms
Melanoma
Early Detection of Cancer
Genetic Research
Research
Health Personnel
Registries
Pancreas
Neoplasms

All Science Journal Classification (ASJC) codes

  • Genetics(clinical)

Cite this

@article{140fa28d6f00438da2e21f9e75801b17,
title = "Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result",
abstract = "Purpose: This study examined whether participants who learned research results related to a germline CDKN2A variant known to be associated with increased risk of pancreatic cancer and malignant melanoma would pursue confirmatory testing and cancer screening, share the genetic information with health care providers and family, and change risk perceptions. Methods: Participants were pancreas research registry enrollees whose biological sample was tested in a research laboratory for the variant. In total, 133 individuals were invited to learn a genetic research result and participate in a study about the disclosure process. Perceived cancer risk, screening intentions, and behaviors were assessed predisclosure, immediately postdisclosure, and six months postdisclosure. Results: Eighty individuals agreed to participate and 63 completed the study. Immediately postdisclosure, carriers reported greater intentions to undergo pancreatic cancer and melanoma screening (p values ≤0.024). Seventy-three percent of carriers (47.5{\%} noncarriers) intended to seek confirmatory testing within six months and 20{\%} (2.5{\%} noncarriers) followed through. All participants shared results with ≥1 family member. More carriers shared results with their health care provider than noncarriers (p = 0.028). Conclusion: Recipients of cancer genetic research results may not follow through with recommended behaviors (confirmatory testing, screening), despite stated intentions. The research result disclosure motivated follow-up behaviors among carriers more than noncarriers.",
author = "Leof, {Emma R.} and Xuan Zhu and Rabe, {Kari G.} and McCormick, {Jennifer B.} and Petersen, {Gloria M.} and {Radecki Breitkopf}, Carmen",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41436-019-0517-y",
language = "English (US)",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",

}

Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result. / Leof, Emma R.; Zhu, Xuan; Rabe, Kari G.; McCormick, Jennifer B.; Petersen, Gloria M.; Radecki Breitkopf, Carmen.

In: Genetics in Medicine, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result

AU - Leof, Emma R.

AU - Zhu, Xuan

AU - Rabe, Kari G.

AU - McCormick, Jennifer B.

AU - Petersen, Gloria M.

AU - Radecki Breitkopf, Carmen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: This study examined whether participants who learned research results related to a germline CDKN2A variant known to be associated with increased risk of pancreatic cancer and malignant melanoma would pursue confirmatory testing and cancer screening, share the genetic information with health care providers and family, and change risk perceptions. Methods: Participants were pancreas research registry enrollees whose biological sample was tested in a research laboratory for the variant. In total, 133 individuals were invited to learn a genetic research result and participate in a study about the disclosure process. Perceived cancer risk, screening intentions, and behaviors were assessed predisclosure, immediately postdisclosure, and six months postdisclosure. Results: Eighty individuals agreed to participate and 63 completed the study. Immediately postdisclosure, carriers reported greater intentions to undergo pancreatic cancer and melanoma screening (p values ≤0.024). Seventy-three percent of carriers (47.5% noncarriers) intended to seek confirmatory testing within six months and 20% (2.5% noncarriers) followed through. All participants shared results with ≥1 family member. More carriers shared results with their health care provider than noncarriers (p = 0.028). Conclusion: Recipients of cancer genetic research results may not follow through with recommended behaviors (confirmatory testing, screening), despite stated intentions. The research result disclosure motivated follow-up behaviors among carriers more than noncarriers.

AB - Purpose: This study examined whether participants who learned research results related to a germline CDKN2A variant known to be associated with increased risk of pancreatic cancer and malignant melanoma would pursue confirmatory testing and cancer screening, share the genetic information with health care providers and family, and change risk perceptions. Methods: Participants were pancreas research registry enrollees whose biological sample was tested in a research laboratory for the variant. In total, 133 individuals were invited to learn a genetic research result and participate in a study about the disclosure process. Perceived cancer risk, screening intentions, and behaviors were assessed predisclosure, immediately postdisclosure, and six months postdisclosure. Results: Eighty individuals agreed to participate and 63 completed the study. Immediately postdisclosure, carriers reported greater intentions to undergo pancreatic cancer and melanoma screening (p values ≤0.024). Seventy-three percent of carriers (47.5% noncarriers) intended to seek confirmatory testing within six months and 20% (2.5% noncarriers) followed through. All participants shared results with ≥1 family member. More carriers shared results with their health care provider than noncarriers (p = 0.028). Conclusion: Recipients of cancer genetic research results may not follow through with recommended behaviors (confirmatory testing, screening), despite stated intentions. The research result disclosure motivated follow-up behaviors among carriers more than noncarriers.

UR - http://www.scopus.com/inward/record.url?scp=85064597601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064597601&partnerID=8YFLogxK

U2 - 10.1038/s41436-019-0517-y

DO - 10.1038/s41436-019-0517-y

M3 - Article

C2 - 30992552

AN - SCOPUS:85064597601

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

ER -